BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murer P, Neri D. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. N Biotechnol 2019;52:42-53. [PMID: 30991144 DOI: 10.1016/j.nbt.2019.04.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Rekad Z, Izzi V, Lamba R, Ciais D, Van Obberghen-schilling E. The Alternative Matrisome: alternative splicing of ECM proteins in development, homeostasis and tumor progression. Matrix Biology 2022. [DOI: 10.1016/j.matbio.2022.05.003] [Reference Citation Analysis]
2 Mock J, Stringhini M, Villa A, Weller M, Weiss T, Neri D. An engineered 4-1BBL fusion protein with "activity on demand". Proc Natl Acad Sci U S A 2020;117:31780-8. [PMID: 33239441 DOI: 10.1073/pnas.2013615117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Corti A, Calimeri T, Curnis F, Ferreri AJM. Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α. Pharmaceutics 2022;14:1414. [DOI: 10.3390/pharmaceutics14071414] [Reference Citation Analysis]
4 Joshi S. Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions. Cancers (Basel) 2020;12:E2057. [PMID: 32722460 DOI: 10.3390/cancers12082057] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
5 Zheng X, Wu Y, Bi J, Huang Y, Cheng Y, Li Y, Wu Y, Cao G, Tian Z. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cell Mol Immunol 2022;19:192-209. [PMID: 35043005 DOI: 10.1038/s41423-021-00786-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Uricoli B, Birnbaum LA, Do P, Kelvin JM, Jain J, Costanza E, Chyong A, Porter CC, Rafiq S, Dreaden EC. Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. Adv Healthc Mater 2021;10:e2002214. [PMID: 33690997 DOI: 10.1002/adhm.202002214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
7 Schliemann C, Hemmerle T, Berdel AF, Angenendt L, Kerkhoff A, Hering JP, Heindel W, Hartmann W, Wardelmann E, Chawla SP, de Braud F, Lenz G, Neri D, Kessler T, Berdel WE. Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas. Eur J Cancer 2021;150:143-54. [PMID: 33901793 DOI: 10.1016/j.ejca.2021.03.038] [Reference Citation Analysis]
8 Yang F, Gong Y, Yu N, Yao L, Zhao X, Hong S, Wang S, Chen B, Xu Y, Pang G, Wang H, Guo Y, Li Y, Guo Y, Xu Z. ST36 Acupuncture Alleviates the Inflammation of Adjuvant-Induced Arthritic Rats by Targeting Monocyte/Macrophage Modulation. Evid Based Complement Alternat Med 2021;2021:9430501. [PMID: 33727948 DOI: 10.1155/2021/9430501] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Arora S, Cooper PR, Friedlander LT, Rizwan S, Seo B, Rich AM, Hussaini HM. Potential application of immunotherapy for modulation of pulp inflammation: opportunities for vital pulp treatment. Int Endod J 2021;54:1263-74. [PMID: 33797765 DOI: 10.1111/iej.13524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Filin IY, Solovyeva VV, Kitaeva KV, Rutland CS, Rizvanov AA. Current Trends in Cancer Immunotherapy. Biomedicines 2020;8:E621. [PMID: 33348704 DOI: 10.3390/biomedicines8120621] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Xu H, Shi M, Shao C, Li H, Wu J, Yu Y, Fang F, Guo Y, Xiao W. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives. Microb Cell Fact 2021;20:115. [PMID: 34107983 DOI: 10.1186/s12934-021-01605-3] [Reference Citation Analysis]
12 Silver AB, Leonard EK, Gould JR, Spangler JB. Engineered antibody fusion proteins for targeted disease therapy. Trends Pharmacol Sci 2021;42:1064-81. [PMID: 34706833 DOI: 10.1016/j.tips.2021.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 [DOI: 10.1101/739987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Mortensen MR, Mock J, Bertolini M, Stringhini M, Catalano M, Neri D. Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors. Oncotarget 2020;11:3972-83. [PMID: 33216834 DOI: 10.18632/oncotarget.27772] [Reference Citation Analysis]
15 Garcia-Lacarte M, Grijalba SC, Melchor J, Arnaiz-Leché A, Roa S. The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. Cancers (Basel) 2021;13:4683. [PMID: 34572910 DOI: 10.3390/cancers13184683] [Reference Citation Analysis]
16 Harris KE, Lorentsen KJ, Malik-Chaudhry HK, Loughlin K, Basappa HM, Hartstein S, Ahmil G, Allen NS, Avanzino BC, Balasubramani A, Boudreau AA, Chang K, Cuturi MC, Davison LM, Ho DM, Iyer S, Rangaswamy US, Sankaran P, Schellenberger U, Buelow R, Trinklein ND. A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Sci Rep 2021;11:10592. [PMID: 34011961 DOI: 10.1038/s41598-021-90096-8] [Reference Citation Analysis]
17 Du Y, Xu J. Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. Adv Mater 2021;33:e2103114. [PMID: 34585802 DOI: 10.1002/adma.202103114] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Gouyou B, Millul J, Villa A, Cazzamalli S, Neri D, Matasci M. Sortase-Mediated Site-Specific Modification of Interleukin-2 for the Generation of a Tumor-Targeting Acetazolamide-Cytokine Conjugate. ACS Omega 2020;5:26077-83. [PMID: 33073134 DOI: 10.1021/acsomega.0c03592] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021;6:402. [PMID: 34824210 DOI: 10.1038/s41392-021-00791-1] [Reference Citation Analysis]
20 Ongaro T, Guarino SR, Scietti L, Palamini M, Wulhfard S, Neri D, Villa A, Forneris F. Inference of molecular structure for characterization and improvement of clinical grade immunocytokines. J Struct Biol 2021;213:107696. [PMID: 33493635 DOI: 10.1016/j.jsb.2021.107696] [Reference Citation Analysis]
21 Mock J, Pellegrino C, Neri D. A universal reporter cell line for bioactivity evaluation of engineered cytokine products. Sci Rep 2020;10:3234. [PMID: 32094407 DOI: 10.1038/s41598-020-60182-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Bentley ER, Little SR. Local delivery strategies to restore immune homeostasis in the context of inflammation. Adv Drug Deliv Rev 2021;178:113971. [PMID: 34530013 DOI: 10.1016/j.addr.2021.113971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
23 Sehnert B, Burkhardt H, Dübel S, Voll RE. Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases. Cells 2020;9:E1627. [PMID: 32640727 DOI: 10.3390/cells9071627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Kontermann RE, Ungerechts G, Nettelbeck DM. Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. MAbs 2021;13:1982447. [PMID: 34747345 DOI: 10.1080/19420862.2021.1982447] [Reference Citation Analysis]
25 Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Front Immunol 2020;11:1986. [PMID: 32983137 DOI: 10.3389/fimmu.2020.01986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
26 Aghlara-Fotovat S, Nash A, Kim B, Krencik R, Veiseh O. Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies. Drug Deliv Transl Res 2021. [PMID: 34176099 DOI: 10.1007/s13346-021-01018-0] [Reference Citation Analysis]
27 Corbellari R, Nadal L, Villa A, Neri D, De Luca R. The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors. Anticancer Drugs 2020;31:799-805. [PMID: 32304410 DOI: 10.1097/CAD.0000000000000938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Liu B, Singh K, Gong S, Canakci M, Osborne BA, Thayumanavan S. Protein-Antibody Conjugates (PACs): A Plug-and-Play Strategy for Covalent Conjugation and Targeted Intracellular Delivery of Pristine Proteins. Angew Chem Int Ed Engl 2021;60:12813-8. [PMID: 33768625 DOI: 10.1002/anie.202103106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]